



## **CLL Live 2018 - Interact with the experts, network with other patients**

Register **NOW** for CLL Live 2018, April 19-21 in Niagara Falls, Ontario. Registration is limited, avoid the wait list. Registration links, agenda, hotel reservation info and other details are posted on the [cllpag.ca](http://cllpag.ca) and [lymphoma.ca](http://lymphoma.ca) websites. Questions should be directed to: [cll.live.canada@gmail.com](mailto:cll.live.canada@gmail.com)

Here are some comments by past attendees:

**Wayne Wells:** “CLL is a big topic that takes time to understand. The upcoming CLL Live conference is an opportunity to do so in a most pleasant way. Here you can meet some of the world’s outstanding Onc/researchers and meet up with members of our community to absorb information including the latest treatment breakthroughs while dining on great food and viewing the wonder of Niagara Falls. Don’t miss this one! “

**Pat Kennedy:** “If you have CLL and have not been to one of these conferences it is a MUST! Being in a room with about 300 other people - all CLL patients and caregivers - is very empowering! And the speakers are tops in the field.”

---

## **Ibrutinib for High Risk Untreated Patients Approved in Ontario**

Ontario has joined Quebec, British Columbia, Saskatchewan and Manitoba in funding ibrutinib (Imbruvica) for untreated patients. The **initial treatment criteria** are: Patients with previously untreated chronic lymphocytic leukemia (CLL)/ small lymphocytic lymphoma (SLL) who present with one of the following:

- chromosome 17p deletion; OR
- TP 53 mutation; OR
- unmutated immunoglobulin heavy chain variable region (IgHV).

**Renewal criteria:** Patient has experienced no disease progression while on Imbruvica therapy

- Initial and renewal approval period: 1 year

---

## **CLLPAG Participates in the Canadian CLL Research Meeting**

Each year, Canadian and international scientists and clinicians get together in Winnipeg to discuss the latest CLL/SLL research. For the past 9 years, CLLPAG has been invited to the [CLL Research Meeting](#) to report on our activities and report back to members about the latest research. Board member Judith Watt-Watson’s report ([13th-Canadian-CLL-Research-Meeting-Report.2017](#)) from October 2017 is posted on our website.